Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed

Glecaprevir/pibrentasvir (GLE/PIB) is a pan-genotype anti-hepatitis C virus (HCV) therapy with high efficacy and safety. However, evidence supporting retreatment following failure of the GLE/PIB regimen is limited. We herein report 3 non-cirrhotic cases involving two men aged 51 and 58 years old and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonomura, Ayami, Tamori, Akihiro, Hai, Hoang, Kozuka, Ritsuzo, Fujii, Hideki, Uchida-Kobayashi, Sawako, Enomoto, Masaru, Kawada, Norifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627798/
https://www.ncbi.nlm.nih.gov/pubmed/34024853
http://dx.doi.org/10.2169/internalmedicine.7028-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627798/
https://www.ncbi.nlm.nih.gov/pubmed/34024853
http://dx.doi.org/10.2169/internalmedicine.7028-21

Ejemplares similares